Daratumumab for primary antiphospholipid syndrome
Treatments studied
Part of Immune system & allergy clinical trials.
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70.
- You completed COVID-19, shingles, and (if available) flu vaccines at least 14 days before starting.
- You have APS confirmed by prior clot or pregnancy-related APS problems (as defined by specific medical criteria).
- Your blood tests show “triple positive” APS antibodies from the last 5 years and are confirmed at screening.
- If you’ve had a blood clot before, you must be on warfarin or low-molecular-weight heparin (LMWH).
- You can follow study visits and give written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
This trial looks at people who have symptoms of antiphospholipid syndrome (APS) but test negative for the usual antibodies. It will compare these patients to those with positive antibody tests to better understand the condition and improve diagnosis and treatment.
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
This study looks at genetic (inherited) risk factors in people who have antiphospholipid antibodies and related symptoms. Your results may help researchers better predict who is at risk and improve care for antiphospholipid antibody syndrome.
This study tests whether the drug sirolimus (Rapamune) is safe and effective for people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may offer a new option for those whose current treatment is stable.
Hear when a new Autoimmune Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.